Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
News|Articles|October 8, 2026
Conference Preview: Fall Clinical Dermatology Conference 2026
Author(s)Tim Smith
Fact checked by: Chelsie Derman
HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.
Advertisement
Advertisement
HCPLive is providing on-site coverage of the 2026 Fall Clinical Dermatology Conference, held October 8 to 11 at the Wynn Las Vegas, featuring expert-led therapeutic updates and interviews with dermatology leaders.¹,²
Related to this article
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Advertisement
Advertisement